[On the use of 2-beta-hydroxyphenetylaminopyridine 1-(p-hydroxyphenyl)-2-phenyl-3-hydroxy-4-n-butyl-5-pyrazolinonate in venous and arterial vasculopathies].
D000328:Adult; D000368:Aged; D001158:Arteries / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009991:Oscillometry; D010991:Plethysmography; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy; D013817:Thermography; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014680:Veins / Q000187:drug effects
D011720:Pyrazoles; D011725:Pyridines
L'impiego dell'1 (p-idrossifenil)-2-fenil-3-idrossi-4-n-butil-5-pirazolinonato di 2-beta-idrossifenetilaminopiridina in vasculopatie venose ed arteriose.